Document Detail


Antiplatelet therapy for improving post-PCI outcomes: interpreting current treatment guidelines for optimal management of the post-ACS patient.
MedLine Citation:
PMID:  19355809     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Dual antiplatelet therapy with a thienopyridine in combination with aspirin for 1 to 6 months after stenting has been recommended by the manufacturers to reduce ischemic cardiovascular events and thrombosis after coronary stenting, whereas the current leading guidelines recommend dual antiplatelet therapy for 12 months following percutaneous coronary intervention in all patients not at high risk of bleeding. Despite the established benefits of dual antiplatelet therapy in acute coronary syndrome (ACS) patients, there are concerns regarding the risk of major bleeding. The risks, benefits, and complexity identified in these interventional trials are communicated in this article to enable well-informed therapeutic decisions. Thienopyridine nonresponsiveness and variability of response are emerging as significant concerns in ACS patients that may lead to poor long-term cardiovascular outcomes. Current research on thienopyridine responsiveness and evidence-based mechanisms for overcoming thienopyridine nonresponsiveness are discussed. In addition, adherence to dual antiplatelet therapy is critical but difficult to achieve, and a considerable proportion of patients (1 of 7) discontinue therapy before 30 days of drug-eluting stent implantation. It has been established that premature discontinuation of thienopyridine therapy is associated with a marked increase in the risk of stent thrombosis (and consequently myocardial infarction and/or death) and is the leading independent predictor of stent thrombosis in multivariate analyses. The factors related to premature cessation of thienopyridine therapy are listed with recommendations for minimizing the complications arising as a result of premature discontinuation.
Authors:
Jason Cross
Related Documents :
7179639 - Percutaneous nephrostomy and antegrade ureteral stent insertion.
19362519 - The role of routine postoperative stentograms in the pediatric patient undergoing excis...
10445799 - Results of percutaneous plastic stents for malignant distal biliary obstruction followi...
8657909 - Iliofemoral venous stenoses: effectiveness of treatment with metallic endovascular stents.
10466599 - Long-segment congenital tracheal stenosis: treatment by slide-tracheoplasty.
18317849 - Treatment of thoracic esophageal anastomotic leaks and esophageal perforations with end...
9486929 - Prevalence of activated protein c resistance in acute myocardial infarction in japan.
12750849 - Late-term reconstruction of lateral ankle ligaments using a split peroneus brevis tendo...
19732429 - Effectiveness of complete conservative treatment for adolescent idiopathic scoliosis (b...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  The American journal of managed care     Volume:  15     ISSN:  1936-2692     ISO Abbreviation:  Am J Manag Care     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-04-09     Completed Date:  2009-11-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9613960     Medline TA:  Am J Manag Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S48-53     Citation Subset:  H    
Affiliation:
Department of Pharmacy Practice, Massachusetts College of Pharmacy and Health Sciences, 19 Foster St, Ste 510, Worcester, MA 01608, USA. jason.cross@mcphs.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*,  mortality,  therapy
Angioplasty, Transluminal, Percutaneous Coronary*
Aspirin / therapeutic use*
Fibrinolytic Agents / therapeutic use
Humans
Platelet Aggregation Inhibitors / therapeutic use*
Practice Guidelines as Topic*
Pyridines / therapeutic use*
Stents
Time Factors
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors; 0/Pyridines; 0/thienopyridine; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and ...
Next Document:  Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders...